A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

This is a single-arm, multicenter, exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection in patients with unresectable, non-metastatic HCC. The primary endpoint is PFS as assessed by the investigator based on RECIST v1.1 criteria.

NCT Number	NCT07128251
Lead Sponsor	Anhui Provincial Hospital Collaborators: Qilu Hospital of Shandong University, Henan Provincial People's Hospital, First Affiliated Hospital of Guangxi Medical University, Shanxi Province Cancer Hospital, Xi'an International Medical Center Hospital, The Second Affiliated Hospital of Harbin Medical University
Conditions	Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1, CTLA-4, TACE
Enrollment	47 participants
Start Date	2025-08-20
Primary Completion	2028-01-30 (estimated)
Study Completion	2029-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-17